This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
After Golden Cross, Accuray (ARAY)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Earnings Estimates Rising for Accuray (ARAY): Will It Gain?
by Zacks Equity Research
Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's What Could Help Accuray (ARAY) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer
by Zacks Equity Research
Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
by Zacks Equity Research
Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 0.00% and 9.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS
by Zacks Equity Research
Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
by Zacks Equity Research
Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
Accuray (ARAY) Down 13.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.
New Strong Sell Stocks for April 30th
by Zacks Equity Research
ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.
Accuray (ARAY) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and 2.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) registers growth in Service revenues during fiscal Q2.
Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
by Zacks Equity Research
Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy
by Zacks Equity Research
Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.